Bengt Simonsson - Concepedia

Author

Bengt Simonsson

Uppsala University Hospital

Also Known As

B Simonsson, B. SIMONSSON, B. Simonsson, BENGT SIMONSSON, Baccarani, Michele, Bengt Simonsson, Luke P Akard

248

Publications

18K

Citations

H-Index

Concepts

All Affiliations

Uppsala University Hospital Uppsala University Karolinska University Hospital Örebro University Hospital Helsinki University Hospital

About

Bengt Simonsson is an author at Uppsala University Hospital specializing in medicine, hematology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	50	2.9K
2	Health Sciences	10	10	265
3	Biomedical Engineering	2	2	69
4	Engineering	1	1	34
5	Public Health	1	1	250

Bengt Simonsson

123

Publications

13.8K

Citations

H-Index

Page 1

	Year	Citations
Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Stephen G. O’Brien, François Guilhot, Richard A. Larson, New England Journal of Medicine	2003	3.5K
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia Brian Druker, François Guilhot, Stephen G. O’Brien, New England Journal of Medicine	2006	3.5K
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score Joerg Hasford, Michele Baccarani, Verena Hoffmann, Blood	2011	492
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study Oliver G. Ottmann, Hervé Dombret, Giovanni Martinelli, Blood	2007	369
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy Satu Mustjoki, Marja Ekblom, T. Petteri Arstila, Leukemia MedicineMalignant Blood DisorderImmunologyImmune Checkpoint InhibitorCell Biology	2009	316
Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia Markus Pfirrmann, Michele Baccarani, Joëlle Guilhot, Leukemia Hematological MalignancyChronic Myeloid LeukemiaOncologyLongevityMixed-phenotype Acute Leukemia	2015	289
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries Verena Hoffmann, Michele Baccarani, Joerg Hasford, Leukemia Hematological MalignancyClinical PopulationClinical EpidemiologyHematologyEuropean Countries	2015	250
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study Michele Baccarani, Gianantonio Rosti, Fausto Castagnetti, Blood	2009	196
Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia Bengt Simonsson, Tobias Gedde‐Dahl, Berit Markevärn, Blood	2011	194
Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups Philip B. McGlave, Paolo de Fabritiis, A. B. Deisseroth, The Lancet Hematological MalignancyAutologous TransplantsTransplantationMarrow TransplantationStem Cell Transplantation	1994	176

Page 1